ImaRx Therapeutics Reports Second Quarter Ended 2009 Financial Results
11. August 2009 07:00 ET
|
ImaRx Therapeutics, Inc.
REDMOND, Wash., Aug. 11, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a development-stage biopharmaceutical company, whose research and development efforts have focused on the...
ImaRx Therapeutics Reports First Quarter Ended 2009 Financial Results
14. Mai 2009 16:30 ET
|
ImaRx Therapeutics, Inc.
REDMOND, Wash., May 14, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a development-stage biopharmaceutical company focused on the development of new treatments for vascular...
ImaRx Therapeutics Reports Fourth Quarter and Year Ended 2008 Financial Results
06. März 2009 18:00 ET
|
ImaRx Therapeutics, Inc.
REDMOND, Wash., March 6, 2009 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a biopharmaceutical company focused on the development of new treatments for vascular disorders leveraging its...
ImaRx Therapeutics Reports Third Quarter Ended 2008 Financial Results
13. November 2008 08:00 ET
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Nov. 13, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (OTCBB:IMRX), a biopharmaceutical company focused on the development of new treatments for vascular disorders leveraging its...
ImaRx Therapeutics Receives NASDAQ Delisting Notification
17. Oktober 2008 07:00 ET
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Oct. 17, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced that it has been advised by The Nasdaq Stock Market ("NASDAQ") pursuant to Marketplace Rule 4300...
ImaRx Therapeutics Divests Urokinase Franchise to Microbix Biosystems
24. September 2008 06:00 ET
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Sept. 24, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced that it has divested its urokinase business to Microbix Biosystems, Inc. (TSX:MBX). Through...
ImaRx Therapeutics Receives Notification From NASDAQ Regarding Non-Compliance With NASDAQ's Stockholders' Equity, Market Value, or Net Income Requirements
26. August 2008 17:00 ET
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Aug. 26, 2008 (GLOBE NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today announced that it received a NASDAQ Staff Deficiency Letter on August 20, 2008 indicating, based on the...
ImaRx Therapeutics Reports Second Quarter Ended 2008 Financial Results
14. August 2008 16:00 ET
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Aug. 14, 2008 (PRIME NEWSWIRE) -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX), a biopharmaceutical company with a commercial product, urokinase, and a research and development program...
ImaRx's Clot Dissolving Technology Being Presented at the AHA Conference
04. November 2004 08:30 ET
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Nov. 4, 2004 (PRIMEZONE) -- ImaRx Therapeutics, Inc. (www.imarx.com) is pleased to announce that Jeane M. Tsutsui, MD of the University of Nebraska Medical Center will be presenting...
ImaRx Top Scientist Granted Excellence in Biotechnology Award for Outstanding Achievement in Drug Delivery
01. November 2004 08:30 ET
|
ImaRx Therapeutics, Inc.
TUCSON, Ariz., Nov. 1, 2004 (PRIMEZONE) -- Terry Matsunaga, PharmD, Ph.D., Vice President of Research for ImaRx Therapeutics, Inc. (www.imarx.com) received the Excellence in Biotechnology Award for...